In this interview, we discuss a study of sex differences in the tolerability of anti–programmed death 1 immunotherapy among patients with metastatic melanoma.
Narjust Duma, MD
Advertisement
Articles by Narjust Duma, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
2
ASCO 2026: Practice-Guiding Updates in Bladder and Kidney Cancer
3
VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors
4
GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations
5